Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO) — TORNADO

Resectable Sarcoma Clinical Trial

Official title:
Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Retifanlimab (INCMGA00012) in Patients With Selected Sarcomas

Status Recruiting

Clinical Trial Summary

Multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trial to assess the antitumor activity of retifanlimab (INCMGA00012) in association with neoadjuvant chemotherapy

Clinical Trial Description

This is a multicenter, prospective, open-labeled, 2-arm, non-comparative randomized (1:1) phase II trial. Patients will be randomized between arm A (neodjuvant chemotherapy by doxorubicin + ifosfamide) and arm B (neodjuvant chemotherapy by doxorubicin + ifosfamide and retifanlimab) with one patient randomized in arm A for one patient randomized in arm B. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04968106
Study type	Interventional
Source	Institut Bergonié
Contact	Antoine ITALIANO, MD, PhD
Phone	+33556333333
Email	a.italiano@bordeaux.unicancer.fr
Status	Recruiting
Phase	Phase 2
Start date	December 7, 2022
Completion date	October 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04213794` - Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients	Early Phase 1
Recruiting	`NCT03965234` - Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases	Phase 1/Phase 2
Not yet recruiting	`NCT04199026` - Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma	Early Phase 1
Completed	`NCT04546243` - Osteosarcoma With Resectable Pulmonary Metastasis: A Retrospective Study
Completed	`NCT03823144` - Intravital Microscopy in Human Solid Tumors	N/A